Onyx BiotecNSE:ONYX -0.36%13 Pretax Margin % is 1.45% as of Mar. 2026, which is 83% below its 10-year median of 8.35. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Onyx Biotec ranks worse than 54.53% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Onyx Biotec's Pre-Tax Income for the
six
months ended in Mar. 2026 was ₹5.0 Mil. Onyx Biotec's Revenue for the
six
months ended in Mar. 2026 was ₹348.8 Mil. Therefore, Onyx Biotec's pretax margin for the quarter that ended in Mar. 2026 was 1.45%.
The historical rank and industry rank for Onyx Biotec's Pretax Margin % or its related term are showing as below:
NSE:ONYX'
s Pretax Margin % Range Over the Past 10 Years
Min: -0.61 Med: 8.35 Max: 10.46
Current: -0.61
NSE:ONYX's Pretax Margin % is ranked worse than 54.53% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.505
vs NSE:ONYX: -0.61
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Onyx Biotec Pretax Margin % Related Terms
Onyx Biotec Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Onyx Biotec's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONYX vs ISRG, BDX, MDLN: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, Onyx Biotec's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Biotec Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Onyx Biotec's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onyx Biotec (NSE:ONYX) has a Pretax Margin % of 1.45% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Onyx Biotec and its competitors. This is 83% below median its historical median of 8.35. According to the industry distribution chart, Onyx Biotec ranks #445 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 54.5%.
Is Onyx Biotec's Pretax Margin % too high?
Onyx Biotec's current Pretax Margin % of 1.45% is 83% below median its 10-year median of 8.35. The Medical Devices & Instruments industry median Pretax Margin % is 2.51. Onyx Biotec's value of 1.45% is 42.1% below this industry median. Based on the distribution chart, Onyx Biotec ranks #445 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's Pretax Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Onyx Biotec ranks #445 out of 816 companies for Pretax Margin %. This places Onyx Biotec in the lower half of its industry. The industry median Pretax Margin % is 2.51. Onyx Biotec's value of 1.45% is 42.1% below this benchmark. While the company's 10-year median is 8.35 vs. the industry median of 2.51, Onyx Biotec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.51, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Biotec's current Pretax Margin % of 1.45% is 42.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Onyx Biotec and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Biotec's current Pretax Margin % is 1.45%, which is 83% below median its own 10-year median of 8.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current Pretax Margin % of 1.45%. The current Pretax Margin % is 1.45%, which is 83% below median its 10-year median of 8.35 and 42.1% below the Medical Devices & Instruments industry median of 2.51. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current Pretax Margin % is 1.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score
Get the complete analysis for NSE:ONYX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONYX has been successfully added to your 